Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy.
Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy.
复制标题
DOI：
10.1136/jitc-2020-002086
复制
发表时间：
2021-04
影响因子：
10.9
通讯作者：
Fueyo J
中科院分区：
文献类型：
--
作者：
Shin DH;Nguyen T;Ozpolat B;Lang F;Alonso M;Gomez-Manzano C;Fueyo J
Cancer virotherapy is a paradigm-shifting treatment modality based on virus-mediated oncolysis and subsequent antitumor immune responses. Clinical trials of currently available virotherapies showed that robust antitumor immunity characterizes the remarkable and long-term responses observed in a subset of patients. These data suggest that future therapies should incorporate strategies to maximize the immunotherapeutic potential of oncolytic viruses. In this review, we highlight the recent evidence that the antiviral immunity of the patients may limit the immunotherapeutic potential of oncolytic viruses and summarize the most relevant approaches to strategically redirect the immune response away from the viruses and toward tumors to heighten the clinical impact of viro-immunotherapy platforms.
登录
查看更多内容
影响因子：
4.6
作者：
Aoyama K;Kuroda S;Morihiro T;Kanaya N;Kubota T;Kakiuchi Y;Kikuchi S;Nishizaki M;Kagawa S;Tazawa H;Fujiwara T
通讯作者：
Fujiwara T
影响因子：
2.2
作者：
Ferguson MS;Lemoine NR;Wang Y
通讯作者：
Wang Y
影响因子：
7.3
作者：
Flórez-Grau G;Zubizarreta I;Cabezón R;Villoslada P;Benitez-Ribas D
通讯作者：
Benitez-Ribas D
影响因子：
2.2
作者：
Alvarez-Breckenridge CA;Yu J;Kaur B;Caligiuri MA;Chiocca EA
通讯作者：
Chiocca EA
影响因子：
5.4
作者：
Bradley, Ritu R.;Maxfield, Lori F.;Barouch, Dan H.
通讯作者：
Barouch, Dan H.